Kymera KT-579 Phase 1 Data Meet Study Objectives

The Tip Desk · October 30, 2026 · 3 min read

The clinical-stage degrader company posted a $132.0 million third-quarter net loss, or $1.32 a share, as research spending rose and collaboration revenue fell to zero.

Kymera Therapeutics (KYMR), a clinical-stage biopharmaceutical company developing oral small-molecule degraders for immunological disease, reported a net loss of $132.0 million for the third quarter ended September 30, 2026, or $1.32 a share, compared with $82.2 million, or $0.94 a share, a year earlier.

The widening loss tracked a step-up in research spending as the company advanced its STAT6 and IRF5 programs. Research and development expenses were $128.5 million, versus $74.1 million in the year-ago quarter. The company said the increase was primarily due to investment in the STAT6 program, platform and discovery programs, and continued growth in the research and development organization. Stock-based compensation in R&D was $10.9 million, compared with $8.4 million.

Collaboration revenue was zero in the third quarter of 2026, compared with $2.8 million in the third quarter of 2025, which the company said was all attributable to its collaboration with Gilead. Kymera said it does not expect to recognize additional collaboration revenue in 2026. General and administrative expenses were $18.7 million, versus $17.3 million a year earlier, which the company attributed in part to higher legal and professional fees and personnel, facility and occupancy costs.

Cash, cash equivalents and investments were $1.6 billion as of September 30, 2026, versus $1.5 billion as of June 30, 2026. The company said it expects that cash balance to provide a runway into 2029, beyond multiple clinical inflection points in its pipeline.

On October 29, 2026, Kymera reported positive results from the completed first-in-human Phase 1 healthy-volunteer trial of KT-579, an investigational first-in-class oral degrader of IRF5. The company said the results met or exceeded study objectives. In the multiple ascending dose portion, KT-579 showed deep, sustained IRF5 degradation in blood, with at least 90% median degradation across multiple dose levels and saturation of degradation by dose level 3. Similar reductions were observed in skin.

Using the median of all MAD dose cohorts, the company said KT-579 inhibited 88% of TNFα, 87% of IL-12/23p40, 94% of IL-1β and 98% of IFNβ at Day 14. Gene-expression analyses showed downregulation of inflammatory cytokine, interferon and B-cell associated genes. The safety profile was comparable to placebo, with no serious or severe adverse events and no adverse events leading to discontinuation.

Founder, President and CEO Nello Mainolfi said the findings exceeded the company’s expectations in terms of depth of degradation, safety and pathway suppression. Kymera said it is advancing KT-579, its seventh degrader to enter the clinic, toward a study in lupus patients. The LUMORA Phase 1b trial in systemic lupus erythematosus, a randomized, double-blind, placebo-controlled study in approximately 30 adult patients dosed over 16 weeks, is planned to start by early 2027. The company also said it will present new preclinical KT-579 data at the American College of Rheumatology Convergence conference in Orlando, Florida, November 6–11, 2026.

In October 2026, the last patient received their final dose and completed the week 16 visit in the KT-621 BROADEN2 Phase 2b trial in moderate to severe atopic dermatitis. Enrollment had been completed in June 2026 nearly six months ahead of the original timeline, pulling the topline readout forward to year-end 2026 from prior guidance of mid-2027. Subject to discussions with regulators, the company expects to initiate the first Phase 3 trial in AD by mid-2027. Enrollment remains ongoing in the KT-621 BREADTH Phase 2b asthma trial, with topline data still expected in late 2027.

The first-in-human Phase 1 trial of KT-485 (SAR447971) in healthy volunteers and hidradenitis suppurativa patients is ongoing, with Sanofi leading development, regulatory and commercial efforts. Gilead Sciences is advancing KT-200 in IND-enabling studies to support an IND filing in 2027.

In July 2026, the company appointed Terence Rooney, MD, as Chief Medical Officer and Elizabeth Laws, PhD, as Senior Vice President and Global STAT6 Development Program Leader.